Clinical Trial Update: Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III Study [Phase 3]

View source ↗

Summary

ERASe-Trial, a Phase 3 study evaluating ertugliflozin to reduce arrhythmic burden in patients with heart failure and ICD/CRT devices, has been terminated with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Mid-range Ejection Fraction
• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Ertugliflozin (Steglatro) (ertugliflozin)

Snippet

Sponsor: Medical University of Graz | Conditions: Heart Failure With Reduced Ejection Fraction, Heart Failure With Mid Range Ejection Fraction | Phase 3 | Status: TERMINATED | Results posted: 2025-06-03